We are live on ! Find out more
Corriente Advisors

Corriente Advisors Portfolio holdings

AUM $9.5M Turnover 83.33%
1-Year Est. Return 805.26%
This Fund
S&P 500
This Quarter Est. Return
+82.51%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
+$61.7M
Cap. Flow
+$20.3M
Cap. Flow %
13.14%
Top 10 Hldgs %
95.94%
Holding
21
New
10
Increased
1
Reduced
4
Closed
5
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
SONO icon
Sonos
SONO
+$16.7M
2
QURE icon
uniQure
QURE
+$10.6M
3
REPL icon
Replimune Group
REPL
+$8.58M
4
OCUL icon
Ocular Therapeutix
OCUL
+$4.77M
5
MAXR
Maxar Technologies
MAXR
+$2.73M

Sector Composition

Rank Sector Weight
1 Healthcare 60.68%
2 Technology 36.99%
3 Consumer Discretionary 1.4%
4 Materials 0.59%
5 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
MAXR
1
DELISTED
Maxar Technologies
MAXR
$34.1M 22.11%
1,900,000
+210,900
+12% +$2.73M
2019 Q4
2 quarters
RETA
2
DELISTED
Reata Pharmaceuticals
RETA
$23M 14.91%
147,500
-42,500
-22% -$6.46M
2019 Q4
2 quarters
SONO icon
3
Sonos
SONO
$2.01B
$23M 14.88%
+1,570,000
New +$16.7M
2020 Q2
0 quarters
APTO
4
DELISTED
Aptose Biosciences
APTO
$17.5M 11.33%
6,158
-326
-5% -$1.05M
2019 Q4
2 quarters
CUE icon
5
Cue Biopharma
CUE
$37.6M
$16.2M 10.48%
22,000
-5,333
-20% -$3.86M
2019 Q4
2 quarters
REPL icon
6
Replimune Group
REPL
$1.82B
$12.1M 7.81%
+485,000
New +$8.58M
2020 Q2
0 quarters
QURE icon
7
uniQure
QURE
$1.42B
$8.11M 5.26%
+180,000
New +$10.6M
2020 Q2
0 quarters
OCUL icon
8
Ocular Therapeutix
OCUL
$1.29B
$6M 3.89%
+720,000
New +$4.77M
2020 Q2
0 quarters
CLDX icon
9
Celldex Therapeutics
CLDX
$2.2B
$5.98M 3.87%
+460,000
New +$2.04M
2020 Q2
0 quarters
TSLA icon
10
Tesla
TSLA
$1.48T
$2.16M 1.4%
30,000
– –
2020 Q1
1 quarter
ARWR icon
11
Arrowhead Research
ARWR
$6.17B
$1.73M 1.12%
+40,000
New +$1.41M
2020 Q2
0 quarters
DMAC icon
12
DiaMedica Therapeutics
DMAC
$433M
$1.4M 0.9%
+201,248
New +$898K
2020 Q2
0 quarters
PAAS icon
13
Pan American Silver
PAAS
$13.4B
$912K 0.59%
+30,000
New +$712K
2020 Q2
0 quarters
CRDF icon
14
Cardiff Oncology
CRDF
$69.4M
$869K 0.56%
+173,361
New +$355K
2020 Q2
0 quarters
PVLA icon
15
Palvella Therapeutics
PVLA
$2.13B
$837K 0.54%
3,375
-18,899
-85% -$4.42M
2020 Q1
1 quarter
RWT icon
16
Redwood Trust
RWT
$313M
$525K 0.34%
+75,000
New +$370K
2020 Q2
0 quarters
SDGR icon
17
Schrodinger
SDGR
$1.98B
– –
-60,000
Closed -$2.59M –
VIRX icon
18
DELISTED
Viracta Therapeutics
VIRX
– –
-86,334
Closed -$1.25M –
BLU
19
DELISTED
BELLUS Health
BLU
– –
-148,666
Closed -$1.48M –
EPZM
20
DELISTED
Epizyme
EPZM
– –
-230,000
Closed -$3.57M –

Similar funds

Corriente Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Corriente Advisors held 21 positions worth $154M, up 67% from $92.6M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Corriente Advisors deployed $20.3M of net new capital in Q2 2020, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Sonos: 1,570,000 shares worth $23M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 75% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Reata Pharmaceuticals, an estimated $6.46M trimmed.

  • Corriente Advisors's largest Q2 2020 buy was Sonos: 1,570,000 shares worth $23M.
  • Corriente Advisors added most to Maxar Technologies in Q2 2020, an estimated $2.73M increase.
  • Corriente Advisors's biggest Q2 2020 reduction was Reata Pharmaceuticals, cutting an estimated $6.46M.
  • Corriente Advisors fully exited Epizyme in Q2 2020, selling an estimated $3.57M.
  • Corriente Advisors's ten largest holdings make up 96% of its $154M portfolio in Q2 2020.
  • Corriente Advisors opened 10 new positions and closed 5 in Q2 2020.
  • Corriente Advisors's portfolio value rose 67% quarter-over-quarter to $154M.

Based on Corriente Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.